These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 38272065

  • 1. A Systematic Review of Efficacy and Safety of Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Voncento) in von Willebrand Disease.
    Rugeri L, Thomas W, Schirner K, Heyder L, Auerswald G.
    Thromb Haemost; 2024 Sep; 124(9):828-841. PubMed ID: 38272065
    [Abstract] [Full Text] [Related]

  • 2. An Open-Label Extension Study to Assess the Long-Term Efficacy and Safety of a Plasma-Derived von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Patients with von Willebrand Disease (SWIFT-VWDext Study).
    Lissitchkov T, Klukowska A, Buevich E, Maltceva I, Auerswald G, Stasyshyn O, Seifert W, Rogosch T.
    J Blood Med; 2020 Sep; 11():345-356. PubMed ID: 33117020
    [Abstract] [Full Text] [Related]

  • 3. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.
    Haemophilia; 2010 Jul 01; 16(4):615-24. PubMed ID: 20331755
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).
    Lissitchkov TJ, Buevich E, Kuliczkowski K, Stasyshyn O, Cerqueira MH, Klukowska A, Joch C, Seifert W.
    Blood Coagul Fibrinolysis; 2017 Mar 01; 28(2):152-162. PubMed ID: 27203734
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical Efficacy and Safety of Fanhdi®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study.
    Jiménez-Yuste V, Alvarez-Román MT, Palomo Bravo Á, Galmes BJ, Nieto Hernández MDM, Benítez Hidalgo O, Marzo Alonso C, Pérez González NF, Coll J, Núñez R, Carrasco M, García Candel F, Gonzalez-Porras JR, Hernández García C, Varó Castro MJ, Mir R.
    Clin Appl Thromb Hemost; 2022 Mar 01; 28():10760296221074348. PubMed ID: 35108125
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
    Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB.
    Blood Transfus; 2019 Sep 01; 17(5):391-398. PubMed ID: 30747707
    [Abstract] [Full Text] [Related]

  • 11. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA.
    Blood Coagul Fibrinolysis; 2009 Mar 01; 20(2):89-100. PubMed ID: 19786936
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
    Federici AB, Santoro RC, Santoro C, Pieri L, Santi RM, Barillari G, Borchiellini A, Tosetto A, Zanon E, De Cristofaro R, Mairal E, Mir R.
    Clin Appl Thromb Hemost; 2024 Mar 01; 30():10760296241264541. PubMed ID: 39033425
    [Abstract] [Full Text] [Related]

  • 14. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
    Skotnicki A, Lissitchkov TJ, Mamonov V, Buevich E, Kuliczkowski K, Goranov S, Kłoczko J, Klukowska A, Stankovic S, Gercheva L, Chernova T, Hellmann A, Dmoszyńska A, Zawilska K, Veldman A, Joch C, Seifert W.
    Thromb Res; 2016 Jan 01; 137():119-125. PubMed ID: 26614676
    [Abstract] [Full Text] [Related]

  • 15. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E, Windyga J, European Wilate Study Group.
    Haemophilia; 2009 Jan 01; 15(1):122-30. PubMed ID: 19149848
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J, von Depka-Prondzinski M, European Wilate® Study Group.
    Thromb Haemost; 2011 Jun 01; 105(6):1072-9. PubMed ID: 21437358
    [Abstract] [Full Text] [Related]

  • 17. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.
    Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM.
    J Thromb Haemost; 2007 Jun 01; 5(6):1115-24. PubMed ID: 17403090
    [Abstract] [Full Text] [Related]

  • 18. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P.
    Haemophilia; 2002 Nov 01; 8(6):761-7. PubMed ID: 12410644
    [Abstract] [Full Text] [Related]

  • 19. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.
    Franchini M.
    Blood Transfus; 2008 Sep 01; 6 Suppl 2(Suppl 2):s33-8. PubMed ID: 19105508
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
    Shortt J, Dunkley S, Rickard K, Baker R, Street A.
    Haemophilia; 2007 Mar 01; 13(2):144-8. PubMed ID: 17286766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.